MX2021000516A - Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. - Google Patents
Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.Info
- Publication number
- MX2021000516A MX2021000516A MX2021000516A MX2021000516A MX2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A
- Authority
- MX
- Mexico
- Prior art keywords
- related disease
- prevention
- treating
- preventing
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713211P | 2018-08-01 | 2018-08-01 | |
| US201862764952P | 2018-08-17 | 2018-08-17 | |
| US201862760204P | 2018-11-13 | 2018-11-13 | |
| PCT/JP2019/030283 WO2020027279A1 (en) | 2018-08-01 | 2019-08-01 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000516A true MX2021000516A (es) | 2021-04-12 |
Family
ID=67660420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000516A MX2021000516A (es) | 2018-08-01 | 2019-08-01 | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. |
| MX2025010400A MX2025010400A (es) | 2018-08-01 | 2021-01-14 | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010400A MX2025010400A (es) | 2018-08-01 | 2021-01-14 | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210301004A1 (enExample) |
| EP (2) | EP4445913A3 (enExample) |
| JP (4) | JP6672516B2 (enExample) |
| KR (5) | KR20200033225A (enExample) |
| CN (1) | CN112512563A (enExample) |
| AU (2) | AU2019315213B2 (enExample) |
| BR (1) | BR112021001655A2 (enExample) |
| CA (1) | CA3107618A1 (enExample) |
| CR (1) | CR20210103A (enExample) |
| DE (1) | DE112019003835T5 (enExample) |
| ES (1) | ES2980137T3 (enExample) |
| HR (1) | HRP20240823T1 (enExample) |
| HU (1) | HUE067057T2 (enExample) |
| IL (2) | IL324626A (enExample) |
| MX (2) | MX2021000516A (enExample) |
| MY (1) | MY210523A (enExample) |
| PH (1) | PH12021550226A1 (enExample) |
| PL (1) | PL3829628T3 (enExample) |
| RS (1) | RS65630B1 (enExample) |
| SG (1) | SG10202002898RA (enExample) |
| SM (1) | SMT202400271T1 (enExample) |
| TW (2) | TWI701041B (enExample) |
| WO (1) | WO2020027279A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE449791T1 (de) | 2000-10-10 | 2009-12-15 | Genentech Inc | Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung |
| MXPA04001301A (es) | 2001-08-17 | 2004-07-08 | Tanox Inc | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| BR112015018438A2 (pt) * | 2013-01-31 | 2017-07-18 | Seoul Nat Univ R&Db Foundation | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento |
| EA201791366A1 (ru) * | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| TWI759261B (zh) * | 2015-02-27 | 2022-04-01 | 日商中外製藥股份有限公司 | Ｉｌ－６受體抗體用於製備醫藥組成物的用途 |
| US20190023775A1 (en) * | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| MA53248A (fr) | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | Anticorps anti-c5 à commutation ph améliorée |
| JP7518764B2 (ja) * | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| BR112020010916A2 (pt) * | 2017-12-04 | 2020-11-17 | Ra Pharmaceuticals, Inc | moduladores da atividade do complemento |
-
2019
- 2019-08-01 MX MX2021000516A patent/MX2021000516A/es unknown
- 2019-08-01 JP JP2019142108A patent/JP6672516B2/ja active Active
- 2019-08-01 TW TW108127358A patent/TWI701041B/zh active
- 2019-08-01 KR KR1020197036896A patent/KR20200033225A/ko not_active Ceased
- 2019-08-01 KR KR1020217009235A patent/KR20210037743A/ko not_active Ceased
- 2019-08-01 AU AU2019315213A patent/AU2019315213B2/en active Active
- 2019-08-01 US US17/263,691 patent/US20210301004A1/en active Pending
- 2019-08-01 SM SM20240271T patent/SMT202400271T1/it unknown
- 2019-08-01 WO PCT/JP2019/030283 patent/WO2020027279A1/en not_active Ceased
- 2019-08-01 HU HUE19755447A patent/HUE067057T2/hu unknown
- 2019-08-01 IL IL324626A patent/IL324626A/en unknown
- 2019-08-01 EP EP24174873.0A patent/EP4445913A3/en active Pending
- 2019-08-01 SG SG10202002898RA patent/SG10202002898RA/en unknown
- 2019-08-01 MY MYPI2021000486A patent/MY210523A/en unknown
- 2019-08-01 CA CA3107618A patent/CA3107618A1/en active Pending
- 2019-08-01 EP EP19755447.0A patent/EP3829628B1/en active Active
- 2019-08-01 CR CR20210103A patent/CR20210103A/es unknown
- 2019-08-01 BR BR112021001655-4A patent/BR112021001655A2/pt unknown
- 2019-08-01 TW TW109108378A patent/TWI704157B/zh active
- 2019-08-01 IL IL280475A patent/IL280475B2/en unknown
- 2019-08-01 HR HRP20240823TT patent/HRP20240823T1/hr unknown
- 2019-08-01 DE DE112019003835.4T patent/DE112019003835T5/de active Pending
- 2019-08-01 CN CN201980051238.8A patent/CN112512563A/zh active Pending
- 2019-08-01 PL PL19755447.0T patent/PL3829628T3/pl unknown
- 2019-08-01 RS RS20240695A patent/RS65630B1/sr unknown
- 2019-08-01 KR KR1020247023205A patent/KR20240115904A/ko active Pending
- 2019-08-01 KR KR1020207007296A patent/KR20200033348A/ko not_active Ceased
- 2019-08-01 ES ES19755447T patent/ES2980137T3/es active Active
- 2019-08-01 KR KR1020217009233A patent/KR20210038697A/ko not_active Ceased
-
2020
- 2020-02-18 JP JP2020025071A patent/JP6672533B1/ja active Active
- 2020-03-04 JP JP2020036818A patent/JP2020079331A/ja active Pending
-
2021
- 2021-01-14 MX MX2025010400A patent/MX2025010400A/es unknown
- 2021-01-29 PH PH12021550226A patent/PH12021550226A1/en unknown
-
2024
- 2024-08-02 AU AU2024205486A patent/AU2024205486A1/en not_active Abandoned
-
2025
- 2025-02-07 JP JP2025018896A patent/JP2025065367A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012931A (es) | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. | |
| CR20210103A (es) | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 | |
| CL2018002708A1 (es) | Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| BR112022008294A2 (pt) | Composições de profármaco e métodos de tratamento | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| MX2021013815A (es) | Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer. | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| MX392470B (es) | Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica. | |
| CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| EA202090485A1 (ru) | Способы лечения рака путем ингибирования setd2 | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| MX2020009496A (es) | Metodo para tratar asma o enfermedad alergica. | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| UY36801A (es) | PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM | |
| EA202090827A1 (ru) | Пероральные композиции для лечения гастроэзофагеального рефлюкса | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer |